A "Predictable" Launch by New CEO:
As It Is, Inc. (Ai3), an innovation-focused and patent-driven, intellectual capital development and holding company is taking a unique approach toward attracting financial capital to its proprietary Artificial Inference technology registered as the “AutoGnome”. Ai3’s new CEO has led the effort for the development of an AutoGnomic Financial Predictor capable of continuous online real-time adaption of its knowledge base thus serving both to enable investment decisions and to provide a hedge against competing predictive tools.
Amherst, NY (PRWEB) February 24, 2004
“William “Bill” Dale Koehler took over the Executive Direction of Ai3 & Affiliates effective October 1st, 2002, following three months of a thorough due diligence review of the companies. Bill immediately arranged for an early stage capital infusion from an Angel investor. In early 2003, Ai3 saw completed the spin-off from its managed Affiliate, Gastro Target Corporation, of SmartPill Capsule Technology into SmartPill Diagnostics, Inc. which is now entering “Proof of Principal” clinical trials with a goal to bring the product to market in early 2005. Bill then turned his attention to a complete company restructuring focused initially on a review, reassignment, replacement and extension of the personnel resources. After a complete assessment of our technology road map, he re-prioritized our technology developments based on ease of go-to-market characterizations which led to a decision to focus on a six month Demo effort which has produced an AutoGnomic Financial Predictor. This ‘‘Predictor’’ combines several tested code modules from our AutoGnome PDS,” states company Chairman, Jon Ray Hamann. “Bill led the effort that brought the “Predictor” in well under budget and on time. The “Predictor” is showing remarkably accurate performance in picking stocks, and is commanding the attention of a growing number of Wall Street Financial Special Interests along with prospective Angel investors inquiring about equity positions in our varied reenergized initiatives,” continued Mr. Hamann.
“While our Greenwich, CT.-based Financial Analytics “Predictor” team remains focused on the continued development and commercialization of this product, Bill will be nurturing the further development and introduction of our Artificial Inference technology for product launches in other defined verticals (including Education and Training, Knowledge Technologies, Health and Medicine, and Business Health), where relationships have been cultivated over the past few months. This is proving to be an exciting growth time for Ai3 since we now have a leader who can manage the direction and meaning of the Company vision, generate and sustain collective trust, who has a bias toward action, risk taking, and curiosity and is an infectious source of hope,” says Mr. Hamann.
Ai3, founded in 1999, is located in the Baird Research Incubator at the University at Buffalo in Amherst, New York, with additional development lab locations in Norwich and Greenwich, CT and two in Southeast Pennsylvania.
